141 related articles for article (PubMed ID: 36949601)
1. Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
Jarisch A; Salzmann-Manrique E; Soerensen J; Sach G; Rettinger E; Willasch A; Bakhtiar S; Klarmann D; Bräuninger S; Moser L; Fekadu J; Hutter M; Klingebiel T; Klusmann JH; Bader P; Bonig H
Br J Haematol; 2023 Jun; 201(6):1159-1168. PubMed ID: 36949601
[TBL] [Abstract][Full Text] [Related]
2. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
Stussi G; Halter J; Bucheli E; Valli PV; Seebach L; Gmür J; Gratwohl A; Schanz U; Passweg JR; Seebach JD
Haematologica; 2009 Feb; 94(2):239-48. PubMed ID: 19144657
[TBL] [Abstract][Full Text] [Related]
3. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
Rowley SD; Liang PS; Ulz L
Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
[TBL] [Abstract][Full Text] [Related]
5. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
6. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
7. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
[TBL] [Abstract][Full Text] [Related]
8. Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.
Damodar S; Shanley R; MacMillan M; Ustun C; Weisdorf D
Biol Blood Marrow Transplant; 2017 May; 23(5):795-804. PubMed ID: 28232088
[TBL] [Abstract][Full Text] [Related]
9. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation.
Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Kwon SW; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Br J Haematol; 2003 Feb; 120(4):702-10. PubMed ID: 12588361
[TBL] [Abstract][Full Text] [Related]
10. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
[TBL] [Abstract][Full Text] [Related]
11. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility.
Nussbaumer W; Schwaighofer H; Gratwohl A; Kilga S; Schönitzer D; Nachbaur D; Niederwieser D
Transfusion; 1995 Jul; 35(7):592-5. PubMed ID: 7631393
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants.
Mehta P; Ramprakash S; Raghuram CP; Trivedi D; Dhanya R; Agarwal RK; Faulkner L
Ann Hematol; 2021 Aug; 100(8):2071-2078. PubMed ID: 34148110
[TBL] [Abstract][Full Text] [Related]
13. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
Maciej Zaucha J; Mielcarek M; Takatu A; Little MT; Gooley T; Baker J; Maloney DG; Sandmaier BM; Maris M; Chauncey T; Storb R; Torok-Storb B
Br J Haematol; 2002 Dec; 119(3):740-50. PubMed ID: 12437653
[TBL] [Abstract][Full Text] [Related]
14. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility.
Crysandt M; Soysal H; Jennes E; Holtick U; Mrotzek M; Rehnelt S; Holderried TAW; Wessiepe M; Kunter U; Wilop S; Silling G; Gecht J; Beier F; Brümmendorf TH; Jost E
Eur J Haematol; 2021 Sep; 107(3):324-332. PubMed ID: 34022082
[TBL] [Abstract][Full Text] [Related]
15. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.
Tomac G; Bojanić I; Mazić S; Vidović I; Raos M; Ćepulić BG; Seiwerth RS; Kelečić J; Labar B
Blood Transfus; 2018 Jul; 16(4):397-404. PubMed ID: 28488966
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Zhu KE; Li JP; Zhang T; Zhong J; Chen J
Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
[TBL] [Abstract][Full Text] [Related]
17. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
Badros A; Tricot G; Toor A; Morris C; Guo C; Munshi N; Barlogie B; Cottler-Fox M
Transfusion; 2002 Feb; 42(2):205-9. PubMed ID: 11896336
[TBL] [Abstract][Full Text] [Related]
18. ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.
Chen Y; Wan X; Cao Y; Wang H; Han D; Zhang Y; Yao W; Song K; Fan Q; Zhu X; Sun Z; Liu H
Blood Transfus; 2022 Mar; 20(2):156-167. PubMed ID: 34369864
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
[TBL] [Abstract][Full Text] [Related]
20. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
